Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million

Privately held Agensys brings a proprietary portfolio of cancer targets, a preclinical pipeline of mAbs and small proteins, and antibody manufacturing capabilities.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet